The Value of Tumour Markers in the Detection of Relapse—Lessons Learned from the Swiss Austrian German Testicular Cancer Cohort Study

European Urology Open Science - Tập 50 - Trang 57-60 - 2023
Stefanie Fischer1, Christian Rothermundt1, Odile Stalder2, Angelika Terbuch3, Thomas Hermanns4, Deborah Zihler5, Beat Müller6, Christian D. Fankhauser7, Anita Hirschi-Blickenstorfer8, Bettina Seifert9, Luis Alex Kluth10, Mark-Peter Ufe11, Walter Mingrone12, Arnoud J. Templeton13, Natalie Fischer14, Sacha Rothschild15, Regina Woelky16, Silke Gillessen17,18,19, Richard Cathomas20
1Department of Medical Oncology and Haematology, Cantonal Hospital St Gallen, St Gallen, Switzerland
2CTU Bern, University of Bern, Bern, Switzerland
3Division of Clinical Oncology, Department of Internal Medicine, Medical University of Graz, Comprehensive Cancer Center Graz, Graz, Austria
4Department of Urology, University Hospital Zurich, Zurich, Switzerland
5Department of Medical Oncology and Haematology, Cantonal Hospital Aarau, Aarau, Switzerland
6Department of Medical Oncology, Cantonal Hospital Luzern, Luzern, Switzerland
7Department of Urology, Cantonal Hospital Luzern, Luzern, Switzerland
8Onkozentrum Hirslanden, Clinic Hirslanden, Zurich, Switzerland
9Department of Medical Oncology, Cantonal Hospital Liestal, Basel, Switzerland
10Clinic for Urology, Goethe University, Frankfurt, Germany
11Ammerland Klinik, Westerstede, Germany
12Department of Medical Oncology, Cantonal Hospital Olten, Olten, Switzerland
13Department of Medical Oncology, St. Claraspital and Faculty of Medicine, University of Basel, Switzerland
14Department of Medical Oncology, Cantonal Hospital Winterthur, Winterthur, Switzerland
15Department of Medical Oncology, University Hospital Basel, Basel, Switzerland
16Department of Medical Oncology, Cantonal Hospital Frauenfeld, Frauenfeld, Switzerland
17Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland
18Università della Svizzera italiana, Lugano, Switzerland
19University of Bern, Bern, Switzerland
20Division of Medical Oncology/Haematology, Cantonal Hospital Graubünden, Chur, Switzerland

Tài liệu tham khảo

Gilligan, 2010, American Society of Clinical Oncology Clinical Practice Guideline on uses of serum tumor markers in adult males with germ cell tumors, J Clin Oncol, 28, 3388, 10.1200/JCO.2009.26.4481 Morris, 2000, Recognizing abnormal marker results that do not reflect disease in patients with germ cell tumors, J Urol, 163, 796, 10.1016/S0022-5347(05)67807-X Mohler, 1987, False positive beta-human chorionic gonadotropin in testicular cancer, Urology, 30, 252, 10.1016/0090-4295(87)90247-0 Lempiäinen, 2007, Increased human chorionic gonadotropin due to hypogonadism after treatment of a testicular seminoma, Clin Chem, 53, 1560, 10.1373/clinchem.2007.088518 Albany, 2014, Pitfalls in management of patients with germ cell tumors and slight elevation of serum α-fetoprotein, J Clin Oncol, 32, 2114, 10.1200/JCO.2014.56.0607 Cathomas, 2010, Interdisciplinary evidence-based recommendations for the follow-up of testicular cancer patients: a joint effort, Swiss Med Wkly, 140, 356 Leão, 2021, Circulating MicroRNAs, the next-generation serum biomarkers in testicular germ cell tumours: a systematic review, Eur Urol, 80, 456, 10.1016/j.eururo.2021.06.006 Dieckmann, 2019, Serum levels of microRNA-371a-3p (M371 test) as a new biomarker of testicular germ cell tumors: results of a prospective multicentric study, J Clin Oncol, 37, 1412, 10.1200/JCO.18.01480 Nappi, 2021, Integrated expression of circulating miR375 and miR371 to identify teratoma and active germ cell malignancy components in malignant germ cell tumors, Eur Urol, 79, 16, 10.1016/j.eururo.2020.10.024 Fankhauser, 2022, Detection of recurrences using serum miR-371a-3p during active surveillance in men with stage I testicular germ cell tumours, Br J Cancer, 126, 1140, 10.1038/s41416-021-01643-z
Thông tin
Thông tin xuất bản

European Urology Open Science

Tập 50

57-60

Thông tin tác giả